North William Darden, Kubajak Christopher S, St Martin Brad, Rinker Brian
From the *University of Kentucky Department of Surgery, Division of Plastic and Reconstructive Surgery; and †University of Kentucky College of Medicine, Lexington, KY.
Ann Plast Surg. 2017 Jun;78(6S Suppl 5):S282-S285. doi: 10.1097/SAP.0000000000001041.
Shifting preference for implant-based breast reconstruction has resulted in an increased use of acellular dermal matrix (ADM) in tissue-expander breast reconstruction. The benefits afforded by ADM must be weighed against a potential increased risk for postoperative complications. Dermal autograft-assisted breast reconstruction using autograft harvest from the lower abdomen has been shown to result in equivalent aesthetics and patient satisfaction compared with ADM at a lower cost, with fewer complications. The purpose of this study was to review a series of patients who underwent bilateral mastectomy and immediate dermal autograft-assisted tissue expander (TE) breast reconstruction using the non-cancerous breast as a donor site, comparing the outcomes with a concurrent cohort of patients undergoing ADM-assisted reconstruction to determine the relative safety, cost, and effectiveness of the 2 procedures.
The study population included all patients who underwent dermal autograft-assisted TE breast reconstruction, using the contralateral cancer-free breast as the source of dermal autograft, between 2010 and 2015. The ADM cohort consisted of patients who underwent bilateral mastectomy and immediate ADM-assisted TE breast reconstruction during the same period. Univariate analysis was performed for demographic data, complications, operative cost, and operative time. Data were compared using the Wilcoxon rank sum test for nonparametric data and χ analyses for continuous and categorical variables. Significance was defined as P value less than 0.05.
Seventeen patients received dermal autograft using the non-cancerous breast donor site. Twenty-seven patients who underwent ADM-assisted reconstruction during the same period were identified. Significantly higher cost was demonstrated between groups (ADM, US $9999.87; autograft, US $3924.19; P < 0.0001). No significance difference existed operative time (autograft, 97 min; ADM, 120 min). No difference was found in wound healing complications (ADM, 14.8%; autograft, 23.53%; P = 0.47). No significant difference was found in major complications (ADM, 26%; autograft, 17.65%; P = 0.52) or infectious complications (ADM, 26%; autograft, 17.65%; P = 0.52).
Dermal autograft-assisted breast reconstruction using the contralateral non-cancerous breast as the source of dermal autograft harvest represents a lower cost alternative to ADM without increased risk of postoperative complications.
对基于植入物的乳房重建的偏好转变,导致脱细胞真皮基质(ADM)在组织扩张器乳房重建中的使用增加。ADM带来的益处必须与术后并发症风险的潜在增加相权衡。与ADM相比,使用下腹部自体皮片移植辅助的乳房重建已显示出具有同等的美学效果和患者满意度,成本更低,并发症更少。本研究的目的是回顾一系列接受双侧乳房切除术并使用非癌侧乳房作为供区进行即刻自体皮片移植辅助组织扩张器(TE)乳房重建的患者,将结果与同期接受ADM辅助重建的患者队列进行比较,以确定这两种手术的相对安全性、成本和有效性。
研究人群包括2010年至2015年间所有接受自体皮片移植辅助TE乳房重建的患者,使用对侧无癌乳房作为自体皮片的来源。ADM队列包括同期接受双侧乳房切除术并即刻ADM辅助TE乳房重建的患者。对人口统计学数据、并发症、手术成本和手术时间进行单因素分析。使用Wilcoxon秩和检验对非参数数据进行比较,对连续变量和分类变量进行χ分析。显著性定义为P值小于0.05。
17例患者使用非癌侧乳房供区进行了自体皮片移植。确定了同期27例接受ADM辅助重建的患者。两组之间显示出显著更高的成本(ADM,9999.87美元;自体皮片移植,3924.19美元;P<0.0001)。手术时间无显著差异(自体皮片移植,97分钟;ADM,120分钟)。伤口愈合并发症无差异(ADM,14.8%;自体皮片移植,23.53%;P=0.47)。主要并发症(ADM,26%;自体皮片移植,17.65%;P=0.52)或感染性并发症(ADM,26%;自体皮片移植,17.65%;P=0.52)无显著差异。
使用对侧非癌乳房作为自体皮片来源进行自体皮片移植辅助乳房重建是一种成本较低的ADM替代方案,且不会增加术后并发症的风险。